Wedbush Securities Inc Exelixis, Inc. Transaction History

Wedbush Securities Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 13, 2022	SELL	$15.84 - $21.88 $161,267 - $222,760	-10,181 Closed	0 $0
Q3 2021 Oct 08, 2021	SELL	$16.3 - $21.14 $25,525 - $33,105	-1,566 Reduced 13.33%	10,181 $215,000
Q2 2021 Jul 27, 2021	BUY	$17.95 - $25.56 $843 - $1,201	47 Added 0.4%	11,747 $214,000
Q4 2020 Feb 16, 2021	BUY	$18.39 - $24.8 $11,401 - $15,376	620 Added 5.6%	11,700 $235,000
Q3 2020 Oct 20, 2020	SELL	$20.67 - $26.94 $5,539 - $7,219	-268 Reduced 2.36%	11,080 $271,000
Q2 2020 Jul 16, 2020	BUY	$16.46 - $27.42 $186,788 - $311,162	11,348 New	11,348 $269,000
Q3 2019 Oct 17, 2019	SELL	$17.68 - $22.65 $539,487 - $691,142	-30,514 Closed	0 $0
Q2 2019 Aug 01, 2019	SELL	$18.93 - $24.75 $98,246 - $128,452	-5,190 Reduced 14.54%	30,514 $652,000
Q1 2019 Apr 17, 2019	BUY	$19.6 - $24.76 $55,938 - $70,665	2,854 Added 8.69%	35,704 $850,000
Q4 2018 Jan 31, 2019	SELL	$13.65 - $21.8 $180,876 - $288,871	-13,251 Reduced 28.74%	32,850 $646,000
Q3 2018 Nov 13, 2018	BUY	$15.87 - $22.4 $95,108 - $134,243	5,993 Added 14.94%	46,101 $817,000
Q2 2018 Aug 03, 2018	BUY	$18.56 - $22.45 $480,574 - $581,297	25,893 Added 182.15%	40,108 $863,000
Q1 2018 May 01, 2018	BUY	$22.15 - $31.89 $314,862 - $453,316	14,215 New	14,215 $315,000

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

Stay updated on Wedbush Securities Inc with notifications on news.